IMCR — IMMUNOCORE HLDGS PLC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying IMCR?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their IMCR position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +1 tracked investor added or increased positions last quarter (Ray Dalio)
- +5 tracked investors reported holding IMCR at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About IMMUNOCORE HLDGS PLC (IMCR)
IMMUNOCORE HLDGS PLC (IMCR) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $51M. Across recent filings, tracked investors recorded 4 new positions, 4 increased, 3 reduced, and 2 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in IMCR
How many top investors track IMCR
A small number of top investors own this.
IMCR Ownership Composition
How IMMUNOCORE HLDGS PLC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant98.2%
- Macro1.1%
- Value & Distressed0.7%
Tracked investors currently reporting IMCR
1 tracked investor has since exited this position — listed separately below.
- Izzy EnglanderJun 30, 2026Millennium ManagementShares1.6MValue$50.7M% Portfolio0.02%
- Steve CohenJun 30, 2026Point72 Asset ManagementShares990.3KValue$31.4M% Portfolio0.03%
- Ken GriffinJun 30, 2026Citadel AdvisorsShares652KValue$20.7M% Portfolio0.00%
- Ray DalioJun 30, 2026Bridgewater AssociatesShares36.7KValue$1.2M% Portfolio0.00%
- Howard MarksJun 30, 2026Oaktree Capital ManagementShares833KValue$766.4K% Portfolio0.01%
Previously held IMCR
These investors reported IMCR in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Paul Tudor Jones | Tudor Investment Corp | 22K | $663.3K | Mar 31, 2026 |
Recent activity
- New$751.3KMay 20, 2026
- Unchanged$766.4K(0.00%)Aug 14, 2026
- New$345.4KFeb 13, 2026
- Increased$570.7K(90.21%)May 15, 2026
- Increased$1.2M(93.91%)Aug 14, 2026
- New$11.9MFeb 14, 2025
- Increased$18.6M(55.79%)Jul 21, 2025
- Increased$25.7M(30.58%)Aug 14, 2025
- Reduced$19.5M(-34.69%)Nov 14, 2025
- Sold$0(-100.00%)Feb 17, 2026
- $1.6MMay 15, 2025
- Reduced$663.3K(-61.21%)Aug 14, 2025
- Unchanged$768K(0.00%)Dec 9, 2025
- Reduced$663.3K(-50.26%)May 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
Frequently asked questions
- How many institutional investors hold IMCR?
- 5 tracked institutional investors disclosed a position in IMCR (IMMUNOCORE HLDGS PLC) in their most recent 13F filing.
- Who is the largest institutional holder of IMCR?
- Izzy Englander, Millennium Management, holds the largest disclosed position in IMCR, valued at $51M.
- Did institutional ownership of IMCR increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 4 increased, 3 reduced, and 2 fully exited IMCR.
- Where does this IMCR ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.